Cite
HARVARD Citation
Gantz, I. et al. (2017). A randomized, placebo‐ and sitagliptin‐controlled trial of the safety and efficacy of omarigliptin, a once‐weekly dipeptidyl peptidase‐4 inhibitor, in Japanese patients with type 2 diabetes. Diabetes, obesity & metabolism. 19 (11), pp. 1602-1609. [Online].